CD274 and esophageal squamous cell carcinoma: Median OS in the pembrolizumab–chemotherapy group was 17.7 months (95% CI 13.9–28.5) versus 11.7 months (9.5–19.0) in the placebo–chemotherapy group in all randomly assigned patients (HR, 0.70; 95% CI 0.47–1.03) (Fig. 1a), 17.7 months (13.7–32.9) versus 11.7 months (9.6–18.3) in patients with ESCC (0.67; 0.44–1.01) (Fig. 1b), 16.9 months (13.5–32.9) versus 11.2 months (7.9–15.4) in patients with PD-L1 CPS ≥ 10 (0.54; 0.32–0.88) (Fig. 1c), and 15.8 months (12.8–32.9) versus 10.9 months (7.8–14.6) in patients with ESCC PD-L1 CPS ≥ 10 (0.51; 0.30–0.86) (Fig. 1d).